Shilpa Medicare Board Approves FY26 Audited Results, Recommends Dividend, and Approves Subsidiary Investment
Shilpa Medicare's Board approved FY26 audited financials and recommended a dividend of ₹0.60 per share. Subsidiaries will invest ₹4.44 Crore for a 28% stake in Neo Green Power Project, aiming for completion by 15 June 2026. The company also approved shifting its registered office from Karnataka to Maharashtra.
The dividend recommendation and investment in a subsidiary are material events. The office relocation is a significant administrative change. These factors collectively have a medium impact.
The approval of audited financial results, recommendation of a final dividend, and strategic investment in a renewable energy project indicate positive corporate actions and financial health.
Shilpa Medicare Limited announced the outcome of its Board Meeting held on 22 May 2026. The Board approved the audited financial statements (Standalone & Consolidated) for the financial year ended 31 March 2026, along with the audited financial results for the fourth quarter and the full financial year. A declaration confirming an unmodified audit opinion on the financial statements was also approved.
The Board recommended a final dividend of ₹0.60 per equity share of face value ₹1/- each for FY 2025-26. This dividend, if approved by shareholders at the upcoming Annual General Meeting (AGM), will be paid within statutory timelines.
In terms of appointments, M/s. V.J.Talati & Co. were appointed as Cost Auditors, and M/s. Aneja Associates were appointed as Internal Auditors for FY 2026-27.
The company also announced significant corporate actions. The Board approved the shifting of the company's registered office from Karnataka to Maharashtra, subject to shareholder approval via Postal Ballot and other necessary approvals. Consequently, a notice for Postal Ballot will be issued for this purpose, and Mr. Santosh Kumar Gunemoni has been appointed as the Scrutinizer for the postal ballot process.
Furthermore, three wholly-owned subsidiaries – Shilpa Pharma Lifesciences Limited, Shilpa Biologicals Pvt Ltd, and Shilpa Biocare Pvt Ltd – will make an equity investment of 28% in Neo Green Power Project Private Limited for ₹4.44 Crore. This investment is intended to meet the energy requirements for captive power consumption in the subsidiaries and is expected to be completed by 15 June 2026.
The registered offices of these subsidiaries, along with Sampra Holdings Private Limited, will also be shifted from Karnataka to Maharashtra.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.